Disclaimer

Robeco Institutional Asset Management B.V. (Dubai office) is regulated by the Dubai Financial Services Authority (“DFSA”) and only deals with Professional Clients and does not deal with Retail Clients as defined by the DFSA.

Neither information nor any opinion expressed on the website constitutes a solicitation, an offer or a recommendation to buy, sell or dispose of any investment, to engage in any other transaction or to provide any investment advice or service. An investment in a Robeco product should only be made after reading the related legal documents such as management regulations, prospectuses, annual and semi-annual reports, which can be all be obtained free of charge at this website and at the Robeco offices in each country where Robeco has a presence.

Please confirm that you are a professional investor and/or institutional investor and that you have read, understood and accept the terms of use for this website.

I Disagree
The case against the size premium

The case against the size premium

14-12-2016 | From the field

This Research Affiliates research note argues that the size premium does not exist. They acknowledge that long-term US data suggests a size premium of 3.4%, while global data suggests a size premium of 1% since the effect was first documented in the early 1980s.

  • David Blitz
    David
    Blitz
    PhD, Executive Director, Head of Quant Selection Research.

However, they then argue that (1) there is an upward bias in size premium estimates due to inaccurate returns on delisted stocks in major databases, (2) indices and hypothetical portfolios ignore trading costs, (3) the statistical significance of the size premium estimates is likely overstated due to data-mining and reporting bias, (4) the statistical significance is very weak, and (5) there is no outperformance on a risk-adjusted basis.

The authors emphasize that their results do not imply that investors should stop investing in small-cap stocks, only that investors should not expect these stocks as a group to deliver superior returns.

From the field
From the field

Our researchers publish many whitepapers based on their own empirical studies; they also follow quantitative research done by others.

Read all articles
Stay informed on Quant investing with monthly mail updates
Stay informed on Quant investing with monthly mail updates
Subscribe
Subjects related to this article are: